PMID- 27364832
OWN - NLM
STAT- MEDLINE
DCOM- 20170217
LR  - 20191027
IS  - 1875-5453 (Electronic)
IS  - 1389-2002 (Linking)
VI  - 17
IP  - 8
DP  - 2016
TI  - P-gp Inhibition-Based Strategies for Modulating Pharmacokinetics of Anticancer 
      Drugs: An Update.
PG  - 806-826
AB  - BACKGROUND: P-glycoprotein (P-gp), a well known ATP dependent efflux membrane 
      transporter, has been attracting considerable interests of medical researchers 
      due to its efflux pump effect being a primary cause of multidrug resistance (MDR) 
      and poor bioavailability (BA) of anticancer agents. How to resolve the aforesaid 
      problems has become the research hot-points in the medical and pharmaceutical 
      fields. The past three decades have witnessed rapid development of the P-gp 
      inhibition-based strategies used for modulating pharmacokinetics (PK) and thus 
      overcoming MDR and improving BA of anticancer drugs. METHODS: An electronic 
      search of PubMed database from inception to April, 2016 was conducted. 
      Additionally, we searched the reference lists of included studies and carried out 
      a citation search for the included studies via Web of Science to find other 
      potentially relevant studies. RESULTS AND CONCLUSION: Lots of the studies of the 
      P-gp inhibition-based strategies are under preclinical phase and the obtained 
      results are exciting and may represent great promise in the clinical application 
      potential. In order to provide useful information for the development of novel 
      strategies for improving BA of anticancer drugs, this article aims to review the 
      research progress in the P-gp inhibition-based strategies that has been acquired 
      over the last three decades, with focus on the P-gp inhibitors, herbal 
      constituents and pharmaceutical excipients as well as novel P-gp-linked drug 
      delivery systems (DDSs). Additionally, the fundamental knowledge on P-gp also is 
      briefly discussed.
FAU - Yang, Xiaobo
AU  - Yang X
FAU - Liu, Kexin
AU  - Liu K
AD  - Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical 
      University, 9 West Section, Lvshun South Road, Lvshunkou District, Dalian 116044, 
      China. kexinliu@dlmedu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Curr Drug Metab
JT  - Current drug metabolism
JID - 100960533
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B, Member 1)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - ATP Binding Cassette Transporter, Subfamily B, Member 1/*antagonists & 
      inhibitors/chemistry/metabolism
MH  - Animals
MH  - Antineoplastic Agents/*pharmacokinetics
MH  - Humans
EDAT- 2016/07/02 06:00
MHDA- 2017/02/18 06:00
CRDT- 2016/07/02 06:00
PHST- 2016/05/13 00:00 [received]
PHST- 2016/06/14 00:00 [revised]
PHST- 2016/06/23 00:00 [accepted]
PHST- 2016/07/02 06:00 [pubmed]
PHST- 2017/02/18 06:00 [medline]
PHST- 2016/07/02 06:00 [entrez]
AID - CDM-EPUB-76902 [pii]
AID - 10.2174/1389200217666160629112717 [doi]
PST - ppublish
SO  - Curr Drug Metab. 2016;17(8):806-826. doi: 10.2174/1389200217666160629112717.